apo-leflunomide
apotex nz ltd - leflunomide 20mg - tablet - 20 mg - active: leflunomide 20mg excipient: colloidal silicon dioxide crospovidone lactose magnesium stearate - apo-leflunomide is indicated for the treatment of: · rheumatoid arthritis, to improve signs and symptoms to retard joint destruction and to improve functional ability and quality of life. leflunomide may be used in patients who have failed to respond to other treatments or as a first line of treatment in patients who have a contraindication to other treatments. · active psoriatic arthritis. leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease.
apo-leflunomide leflunomide 20mg tablet bottle
arrotex pharmaceuticals pty ltd - leflunomide, quantity: 20 mg - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; maize starch; povidone; colloidal anhydrous silica; lactose monohydrate; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000 - treatment of active rheumatoid arthritis.,treatment of active psoriatic arthritis. leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions).
apo-leflunomide leflunomide 10mg tablet bottle
arrotex pharmaceuticals pty ltd - leflunomide, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; povidone; crospovidone; magnesium stearate; lactose monohydrate; maize starch; titanium dioxide; hypromellose; macrogol 4000 - treatment of active rheumatoid arthritis.,treatment of active psoriatic arthritis. leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions).
apo-leflunomide tablet
apotex inc - leflunomide - tablet - 20mg - leflunomide 20mg - disease-modifying antirheumatic agents
pms-leflunomide tablet
pharmascience inc - leflunomide - tablet - 20mg - leflunomide 20mg - disease-modifying antirheumatic agents
phl-leflunomide tablet
pharmel inc - leflunomide - tablet - 20mg - leflunomide 20mg - disease-modifying antirheumatic agents
dom-leflunomide tablet
dominion pharmacal - leflunomide - tablet - 20mg - leflunomide 20mg - disease-modifying antirheumatic agents
mylan-leflunomide tablet
mylan pharmaceuticals ulc - leflunomide - tablet - 20mg - leflunomide 20mg - disease-modifying antirheumatic agents
nu-leflunomide tablet
nu-pharm inc - leflunomide - tablet - 20mg - leflunomide 20mg - disease-modifying antirheumatic agents
ntp-leflunomide tablet
teva canada limited - leflunomide - tablet - 20mg - leflunomide 20mg - disease-modifying antirheumatic agents